Moderna's Melanoma Data Hold Up to Scrutiny. The Downgrade Is About Price, Not Science.
Published on 10/27/2026 at 14:12 | Editorial boerse-global.de
Moderna shares slipped 2.3% today, with coverage of the weakness pointing to a William Blair downgrade — though that note does not by itself account for the full session's move. The broker cut its recommendation on valuation grounds, a call that lands after the stock had already retreated in the wake of the companies' melanoma study readout.
That earlier slide followed the release of results for the combination of intismeran and Merck's Keytruda. Reuters characterized the drop at the time as profit-taking once the news was out.
What the Phase 3 Actually Showed
The INTerpath-001 trial, run by the two companies, found that the combination cut the risk of recurrence or death by 42% versus Keytruda alone. The partners also reported a 38% reduction in the risk of distant metastasis or death for the combo. Overall survival data, by their own account, were not yet mature. Both companies said Thursday they are in dialogue with regulators.
The statistical backing is solid: a hazard ratio of 0.58 and a p-value below 0.001 for the recurrence-or-death endpoint, and a p-value of 0.002 for distant metastasis or death. Median follow-up ran 24.6 months.
Should investors sell immediately? Or is it worth buying Moderna?
Press reports noted that the 42% figure came in below the 49% seen in an earlier Phase 2b study, and attributed Friday's continued weakness to the market's reaction to the data. Other names in the sector, according to those reports, were largely spared the selling.
Reading the Numbers Without Overreading Them
The result is a genuine argument for the combination's clinical potential — but it measures a risk reduction against a comparator arm, not a guarantee of cure, and says nothing about how much any individual patient stands to gain. Nor can the benefit be pinned on intismeran alone without naming the Keytruda combination that was actually tested.
By the same token, it would be a mistake to treat the sharp share-price reaction as a verdict on the medicine. A stock move answers a different question than a clinical trial does, and it cannot invalidate the treatment effects that were measured.
Approval Is a Forecast, Not a Finding
Moderna chief executive Stéphane Bancel, cited in media reports, said the two companies are pushing hard on a filing for FDA approval and that he expects a green light in 2027. They are also preparing trials in additional cancer types.
Moderna at a turning point? This analysis reveals what investors need to know now.
Those are legitimate things for investors to weigh, but they belong in a different category from the data. An expected approval remains an expectation; planned studies in other tumors are not yet evidence of efficacy in those settings. Valuation should not run further ahead than the demonstrated results can carry it.
Hence a deliberately two-part conclusion. The melanoma data make a persuasive case for the combination's clinical promise, yet they do not justify writing off approval and broader applications as done deals. Neither the selloff nor the study figures alone settles what Moderna is worth. The most defensible stance is enthusiasm for the benefit that has been proven, paired with restraint about what comes next.
Ad
Moderna Stock: New Analysis - 27 October
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
